Aprea Therapeutics Faces Q1'26 Revenue Estimate of Zero Amid Financial Woes
APRE sits 79% above its 52-week low of $0.548 on elevated volume (2.2× avg).
Summary
Aprea Therapeutics is facing a Q1'26 revenue estimate of $0, with an anticipated EPS of ($0.21), ahead of its earnings announcement on May 18. This estimate underscores the company's ongoing financial challenges, which were previously highlighted in its last 10-K filing, noting significant viability concerns, a going concern doubt, and Nasdaq delisting risk. The lack of expected revenue reinforces the precarious commercial position of the company. Traders will be closely watching the actual Q1'26 results for any deviation from these low expectations and for updates on the company's financial stability and strategic path forward.
At the time of this announcement, APRE was trading at $0.98 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $12.1M. The 52-week trading range was $0.55 to $2.22. This news item was assessed with negative market sentiment and an importance score of 7 out of 10. Source: Wiseek News.